2023-12-12 06:11:01 ET
ADC Therapeutics ( NYSE: ADCT ) shares jumped 13% premarket on Tuesday after reporting encouraging early results for a combination therapy for patients with relapsed/refractory follicular lymphoma (FL).
In an investigator-initiated Phase 2 clinical trial, Zynlonta (loncastuximab tesirine-lpyl), a CD19-directed antibody drug conjugate, in combination with monoclonal anti-CD20 antibody rituximab led to 96.3% overall response rate and 85.2% complete response rate in r/r FL patients.
After a median follow-up of 9.7 months, the median progression-free survival (PFS) was not reached, and the 12-month PFS was 92.3%.
The data is from a single-institution study conducted at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Based on the initial results, the investigators are planning a multicenter clinical trial to expand the current cohort and decrease the length of therapy to six cycles. The trial is expected to be launched in the first quarter of 2024.
More on ADC Therapeutics
- ADC Therapeutics: Navigating A Swirling Drain
- ADC Therapeutics SA (ADCT) Q3 2023 Earnings Call Transcript
- ADC Therapeutics receives NYSE notice of non-compliance with continued listing standards
- Seeking Alpha’s Quant Rating on ADC Therapeutics
- Historical earnings data for ADC Therapeutics
For further details see:
ADC Therapeutics rises after promising early data on lymphoma therapy